Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents.
The antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds against Walker 256 carcinosarcoma in comparison to cis-dichlorodiammineplatinum(II) (cisplatin, cis-DDP, NSC 119875) was investigated. The tested compounds showed in this experimental model an enhanced median survival time and a lower toxicity compared to cisplatin.